



PTO/SB/08A/B (09-08)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/646,267-Conf. #9453	
			Filing Date	August 22, 2003	
			First Named Inventor	Kathryn Lindsay BALL	
			Art Unit	1654	
			Examiner Name	D. Lukton	
Sheet	1	of	2	Attorney Docket Number	CCI-007USDV

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
X	B1	EP-0002805-B1	07-11-1979	BASF Aktiengesellschaft		
X	B2	FR-2662698-A1	12-06-1991	Centre National De La Recherche Scientifique		Abstr.
X	B3	WO-93/12251-A1	06-24-1993	Baylor College of Medicine		
X	B4	WO-94/02167-A1	02-03-1994	The Trustees of Princeton University		
X	B5	WO-95/06415-A1	03-09-1995	Baylor College of Medicine		
X	B6	WO-95/13375-A1	05-18-1995	The Johns Hopkins University		
X	B7	WO-95/31995-A1	11-30-1995	Baylor College of Medicine et al.		
X	B8	WO-96/14334-A1	05-17-1996	University of Dundee		
X	B9	WO-97/03681-A1	02-06-1997	Worcester Foundation for Biomedical Research, Inc.		
X	B10	WO-97/42222-A1	11-13-1997	Cyclacel Limited		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
X	C1	Ball, K.L. et al., "Human and plant proliferating-cell nuclear antigen have a highly conserved binding site for the p53-inducible gene product p21WAF1," <i>Eur. J. Biochem.</i> , Vol. 237(3):854-861 (1996)	
X	C2	Chen, Junjie et al., "p21Cip1/Waf1 disrupts the recruitment of human Fen1 by proliferating-cell nuclear antigen into the DNA replication complex," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 93:11597-11602 (1996)	
X	C3	Chen, Junjie et al., "Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA," <i>Nature</i> , Vol. 374(6520):386-388 (1995)	
X	C4	Deng, C. et al., "Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control," <i>Cell</i> , Vol. 82(4):675-684 (1995)	
X	C5	Eastham, James A. et al., "In Vivo Gene Therapy with p53 of p21 Adenovirus for Prostate Cancer," <i>Cancer Research</i> , Vol. 55:5151-5155 (1995)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Not considered

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/646,267-Conf. #9453
		Filing Date	August 22, 2003
		First Named Inventor	Kathryn Lindsay BALL
		Art Unit	1654
		Examiner Name	D. Lukton
		Attorney Docket Number	CCI-007USDV
Sheet	2	of	2

X	C6	El-Deiry, W.S. et al., "WAF1, a potential mediator of p53 tumor suppression," <i>Cell</i> , Vol. 75(4):817-825 (1993)	
X	C7	Flores-Rozas, Herman et al., "Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase $\delta$ holoenzyme," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91:8655-8659 (1994)	
X	C8	Gu, Yong et al., "Inhibition of CDK2 activity <i>in vivo</i> by an associated 20K regulatory subunit," <i>Nature</i> , Vol. 366:707-710 (1993)	
X	C9	Harper, J. Wade et al., "The p21 Cdk-Interacting Protein Cip1 Is a Potent Inhibitor of G1 Cyclin-Dependent Kinases," <i>Cell</i> , Vol. 75:805-816 (1993)	
X	C10	Hiraoka, Lea R. et al., "Sequence of Human FEN-1, a Structure-Specific Endonuclease, and Chromosomal Localization of the Gene ( <i>FEN1</i> ) in Mouse and Human," <i>Genomics</i> , Vol. 25:220-225 (1995)	
X	C11	Nakanishi, Makoto et al., "The C-terminal Region of P21 <sup>SDI1</sup> /WAF1/CIP1 Is Involved in Proliferating Cell Nuclear Antigen Binding but Does Not Appear to Be Required for Growth Inhibition," <i>The Journal of Biological Chemistry</i> , Vol. 270(29):17060-17063 (1995)	
X	C12	Su, Jin-Yuan et al., "Cloning and characterization of the <i>Xenopus</i> cyclin-dependent kinase inhibitor p27 <sup>XIC1</sup> ," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 92:10187-10191 (1995)	
X	C13	Waga, Shou et al., "The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA," <i>Nature</i> , Vol. 369:574-578 (1994)	
X	C14	Waldman, Todd et al., "p21 Is Necessary for the p53-mediated G <sub>1</sub> Arrest in Human Cancer Cells," <i>Cancer Research</i> , Vol. 55:5187-5190 (1995)	
X	C15	Warbrick, Emma et al., "Homologous regions of Fen1 and p21Cip1 compete for binding to the same site on PCNA: a potential mechanism to co-ordinate DNA replication and repair," <i>Oncogene</i> , Vol. 14:2313-2321 (1997)	
X	C16	Zhang, Hui et al., "p21-containing cyclin kinases exist in both active and inactive states," <i>Genes &amp; Development</i> , Vol. 8:1750-1758 (1994)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Not considered

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--